VEGFA, vascular endothelial growth factor A, 7422

N. diseases: 1899; N. variants: 59
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.600 Biomarker disease BEFREE Our observed genetic interaction between PGF and VEGFA appears relevant to psoriasis, a disease with an angiogenic basis, and may influence development of an antiangiogenic approach to treatment. 31545526 2020
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.600 Biomarker disease BEFREE Due to the effect of inhibiting production of VEGF, acitretin can effectively treat psoriasis. 31148871 2020
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.600 GeneticVariation disease BEFREE Haplotype analysis suggests that the coexistence of the polymorphisms rs1799964 (TNF-α), rs2010963 (VEGF), rs833061 (VEGF), and rs6311 (5HT2A) may be a protective factor for psoriasis. 31148856 2020
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.600 AlteredExpression disease BEFREE Topical application or subcutaneous injection of the Fib3 antibody decreased Psoriasis Area and Severity Index and VEGF expression in imiquimod-treated mice. 30146751 2019
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.600 Biomarker disease BEFREE The objective of the study was to elucidate the mechanism by which siRNA-mediated silencing of KRT16 affects keratinocyte proliferation and vascular endothelial growth factor (VEGF) secretion in psoriasis through the extracellular signal-related kinase (ERK) signaling pathway. 30942529 2019
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.600 Biomarker disease BEFREE Prolactin and the vascular endothelial growth factor seem to play a key role in psoriasis pathogenesis regarding hyperproliferation of epidermal keratinocytes and dermal vascular ectasia. 31384319 2019
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.600 Biomarker disease BEFREE In non-erythrodermic PF, VEGF positivity was similar to HI (P = 0.247), and lower than psoriasis (P = 0.049) and PV (P = 0.049). 29489039 2018
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.600 Biomarker disease BEFREE How relevant are vascular endothelial growth factor and intercellular adhesion molecule in the systemic capillary leak syndrome of psoriasis? 29364440 2018
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.600 GeneticVariation disease BEFREE The allele of rs2237051 G increased the erythema during the treatment, and no polymorphism of VEGF and EGF gene was found to be associated with the susceptibility and efficacy in psoriasis. 29843550 2018
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.600 Biomarker disease BEFREE Thalidomide has been reported being able to inhibit the effects of fibroblast growth factor 2 and vascular endothelial growth factor (VEGF), and inhibit tumour necrosis factor-alpha synthesis, and suppress tumour necrosis factor-induced nuclear factor-kappa B activation in Jurkat cells, resulting in suppression of proliferation inflammation, angiogenesis, and the immune system, which are related to the pathogenesis of psoriasis. 28982338 2018
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.600 Biomarker disease BEFREE In this study, we assessed the therapeutic potential of IL-35 recombinant protein in three well-known mouse models: the dextransulfate sodium (DSS)-induced colitis mouse model, the keratin14 (K14)-vascular endothelial growth factor A (VEGF-A)-transgenic (Tg) psoriasis mouse model and the imiquimod (IMQ)-induced psoriasis mouse model. 29193791 2018
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.600 Biomarker disease BEFREE Our results suggest that PEDF act as a multipotent factor in the skin and the imbalance of PEDF and VEGF may be responsible for the transformation from normal skin to psoriasis. 29579411 2018
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.600 AlteredExpression disease BEFREE Vascular endothelial growth factor driving aberrant keratin expression pattern contributes to the pathogenesis of psoriasis. 28928080 2017
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.600 AlteredExpression disease BEFREE Potential value as a novel marker of angiogenesis in patients with psoriasis is also evaluated by assessing possible relation of SCUBE-1 and 3 with disease activity in conjunction with vascular endothelial growth factor (VEGF) levels, as an established marker of angiogenesis. 28238185 2017
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.600 GeneticVariation disease BEFREE However, two other VEGF SNPs, rs833061, and rs699947, showed no association with psoriasis susceptibility. 28803785 2017
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.600 Biomarker disease BEFREE At each step of the psoriasis molecular pathway, different inflammatory cytokines and angiogenic growth factors are involved such as hypoxia inducible factor-1 α (HIF-1 α), vascular endothelial growth factor (VEGF), matrix metalo proteinases (MMPs), basic fibroblast growth factor (bFGF), Angiopoitin-2, interleukin-8 (IL-8), IL-17, and IL-2. 28110689 2017
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.600 Biomarker disease BEFREE In this viewpoint study, the role of VEGF-mediated angiogenesis as a cause for cardiovascular events in patients with psoriasis is explored. 28156019 2017
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.600 Biomarker disease BEFREE Immunostaining analyses in human psoriasis skin lesions and VEGF-A transgenic mouse skin suggested that the ectodomain shedding of LYVE-1 occurred in lymphatic vessels undergoing chronic inflammation. 26966180 2016
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.600 GeneticVariation disease BEFREE This meta-analysis suggests the VEGF +405 C/G polymorphism confers susceptibility to psoriasis in Asians, and that the -460 C/T and -1154 A/G polymorphisms confer susceptibility to psoriasis in Europeans. 26600499 2015
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.600 AlteredExpression disease BEFREE To examine the role of Notch-1 signalling in the pathogenesis of psoriasis, Notch-1, DLL-4, Jagged-1, Hrt-1/Hrt-2, A-SAA, Factor VIII and vascular endothelial growth factor (VEGF) mRNA and/or protein expression in psoriasis skin biopsies, serum and dHMVEC were assessed by immunohistology, dual-immunofluorescence, real-time PCR, ELISA and Western blotting. 24330353 2014
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.600 GeneticVariation disease BEFREE In the current study, we assessed IL-37 in two well-known psoriasis models: a human keratinocyte cell line (HaCaT) and the keratin 14 VEGF-A-transgenic mouse model. 24453242 2014
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.600 Biomarker disease BEFREE Vascular endothelial growth factor (VEGF), the most critical angiogenic factor, is thought to play important roles during the pathogenesis of psoriasis and may be a promising target for treating psoriasis. 25227750 2014
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.600 AlteredExpression disease BEFREE Psoriasis (Ps) is an autoimmune disease characterized by keratinocyte hyperproliferation and chronic inflammation, with increased expression of tumor necrosis factor (TNF) and vascular endothelial growth factor (VEGF). 24587411 2014
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.600 GeneticVariation disease BEFREE Results from the meta-analysis do support the hypothesis that single-nucleotide polymorphism markers at +405C>G, -460C>T, and -1154G>A of the VEGF gene may serve as biological markers of psoriasis. 24678886 2014
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.600 Biomarker disease BEFREE Vascular endothelial growth factor (VEGF), one of the downstream molecules of EGFR and TNF signaling, plays a key role in angiogenesis for developing psoriasis. 25384035 2014